 |
Hikma cuts full-year generics revenue forecastDrugmaker Hikma Pharmaceuticals said trading in its generics unit was below its expectations due to slower-than-anticipated growth in the sales of its gout drug and cut its full-year revenue forecast for the unit. Hikma now expect More… |
Sunday 28 April 2024
